Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cleo DiagnosticsASX:COV -3.23%32 3-Year EBITDA Growth Rate is 0.60% as of Jun. 2026, which is at its 10-year median of 0.60. GuruFocus rates ASX:COV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 688 Medical Devices & Instruments companies, Cleo Diagnostics ranks worse than 63.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 0.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cleo Diagnostics was 0.60% per year. The lowest was 0.60% per year. And the median was 0.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Cleo Diagnostics 3-Year EBITDA Growth Rate Related Terms
ASX:COV vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Cleo Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleo Diagnostics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cleo Diagnostics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.60% mean?
Cleo Diagnostics (ASX:COV) has a 3-Year EBITDA Growth Rate of 0.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cleo Diagnostics and its competitors. This is near median its historical median of 0.60. Over the past decade, Cleo Diagnostics' 3-Year EBITDA Growth Rate has ranged from 0.60 to 0.60. According to the industry distribution chart, Cleo Diagnostics ranks #437 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 63.5%.
Is Cleo Diagnostics' 3-Year EBITDA Growth Rate too high?
Cleo Diagnostics' current 3-Year EBITDA Growth Rate of 0.60% is near median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 0.60. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Cleo Diagnostics' value of 0.60% is 92.6% below this industry median. Based on the distribution chart, Cleo Diagnostics ranks #437 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cleo Diagnostics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Cleo Diagnostics ranks #437 out of 688 companies for 3-Year EBITDA Growth Rate. This places Cleo Diagnostics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Cleo Diagnostics' value of 0.60% is 92.6% below this benchmark. Historically, Cleo Diagnostics' own 3-Year EBITDA Growth Rate has ranged from 0.60 to 0.60 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 8.10, Cleo Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cleo Diagnostics's current 3-Year EBITDA Growth Rate of 0.60% is 92.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Cleo Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleo Diagnostics's current 3-Year EBITDA Growth Rate is 0.60%, which is near median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current 3-Year EBITDA Growth Rate of 0.60%. The current 3-Year EBITDA Growth Rate is 0.60%, which is near median its 10-year median of 0.60 and 92.6% below the Medical Devices & Instruments industry median of 8.10. Cleo Diagnostics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current 3-Year EBITDA Growth Rate is 0.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
32GF Score
Get the complete analysis for ASX:COV
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:COV has been successfully added to your 
